Journal of Psychopharmacology
September 4, 2026
M. Nikolič, Tom Froese, Pedro A. M. Mediano et al.
Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized. Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a...
Physiological research
May 12, 2026
Marcel Bochin, Čestmír Vejmola, Vlastimil Koudelka et al.
Cannabinoids modulate brain network activity, yet the spatial organization and temporal evolution of their electrophysiological effects remain insufficiently characterized in animal models. Here, we investigated how acute oral administration of ?9-tetrahydrocannabinol (THC; 10 mg/kg), cannabidiol (CBD; 10 mg/kg), and their combination influences resting-state EEG dynamics in freely moving rats....
Addiction Biology
March 1, 2026
Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-administration (IVSA). Rats were trained on...
Psychopharmacology
December 13, 2025
David Greguš, Jaroslav Hlinka, Filip Tylš et al.
Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially serving as predictive biomarkers. (Lewis et al. Biomedicines 8(2):34 2020) reported that rostral anterior cingulate cortex thickness predicted emotional experiences under psilocybin, suggesting cortical morphometry as a marker of psychedelic...
Research Square
September 25, 2025
David Greguš, Jaroslav Hlinka, Filip Tylš et al.
Abstract Rationale: Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially serving as predictive biomarkers. Lewis et al. (2020) reported that rostral anterior cingulate cortex thickness predicted emotional experiences under psilocybin, suggesting cortical morphometry as a marker of psychedelic...
Biological Psychiatry Global Open Science
September 1, 2025
Čestmír Vejmola, Klára Šíchová, Kateřina Syrová et al.
4 citations
Psychedelics, particularly psilocin, are increasingly being studied for their mind-altering effects and potential therapeutic applications in psychiatry. Visual hallucinations, especially the illusion of motion in static images, are a hallmark of their action. Despite growing interest, the underlying mechanisms remain poorly understood, as their systematic evaluation in both humans and animals...
The International Journal of Neuropsychopharmacology
August 1, 2025
Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al.
1 citation
Hexahydrocannabinol (HHC) is a new psychoactive substance known for its mind-altering effects and temporary legal status. It is widely used in parts of the Europe and United Kingdom as a legal alternative to ∆9-tetrahydrocannabinol, yet little research has explored its effects and safety. This study examined how HHC is processed in the body, its toxicity, and its impact on behavior in male...
Pharmacological reports : PR
June 16, 2025
Tereza Klučková, Marek Nikolič, Filip Tylš et al.
4 citations
Recent studies intensively explore psilocybin's antidepressant potential, but variables like previous experience, repeated use, setting, and sex remain underexplored. This study examines acute and long-term effects of psilocybin in healthy individuals. A double-blind, placebo-controlled, cross-over study included 40 healthy participants (20 females, mean age 38). Each received two doses of...
Journal of psychopharmacology (Oxford, England)
May 28, 2025
Yana Vella, Kateřina Syrová, Aneta Petrušková et al.
1 citation
Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although the exact underlying molecular mechanisms remain unclear. This study investigates the effects of psilocin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) on synaptogenesis...
October 2, 2024
Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al.
Background and purpose: Hexahydrocannabinol (HHC) is a novel psychoactive substance that has gained attention due to its psychotropic effects and temporary legal status. It is widely abused in several EU and US countries, where it serves as a legal and easily accessible alternative to ∆ 9 -tetrahydrocannabinol (∆ 9 -THC). Despite its widespread use, few studies have examined its in vivo effects...
medRxiv
September 11, 2024
Marek Nikolič, Pedro A. M. Mediano, Tom Froese et al.
6 citations
preprint
Abstract Psilocybin is a classic psychedelic and a novel treatment for mood disorders. Psilocybin induces dose-dependent transient (4-6 hours) usually pleasant changes in perception, cognition, and emotion by non-selectively agonizing the 5-HT 2A receptors and negatively regulating serotonin reuptake, and long-term positive antidepressant effect on mood and well-being. Long-term effects are...
IBRO Neuroscience Reports
November 6, 2023
Tomáš Páleníček, Tereza Klučková, Marek Nikolič et al.
INTRODUCTION: The mechanisms by which the psychedelic drug psilocybin, a novel rapid-acting antidepressant, improves depressive symptoms are still unclear. One candidate mechanism is the impact of the phenomenology of the psychedelic experience, with positive phenomenology hypothesised to be associated with positive long-term outcomes and fearful phenomenology hypothesised to be associated with...
IBRO Neuroscience Reports
October 1, 2023
Čestmír Vejmola, Kateřina Syrová, Klára Šíchová et al.
GABAB receptors are the metabotropic GABA neurotransmitter receptors in the central nervous system constituting a fundamental part of the inhibitory modulation mechanism.These receptors are heterodimers composed of GABAB1 and GABAB2 which function is modulated by the potassium channel tetramerization domain proteins (KCTD) from clade F (KCTD16; KCTD12 and KCTD8).In our experiments we explored...